Growth momentum Novum has a multi-decade track record in early and late phase clinical research with global reach, recent leadership appointment, and active participation in major industry events, signaling potential for expanded engagement in broader CRO services and higher-tier collaborations.

Strategic partnerships Frequent co-appearances with Lambda Therapeutic Research and ongoing exhibition at high-profile industry events (CPHI, SCOPE Summit, J.P. Morgan Healthcare Conference) suggest opportunities for co-sell partnerships, referral networks, and expanded service scopes through alliance-driven deals.

Financial opportunity Revenue range reported at 25 to 50 million with a recent second draw PPP loan and a leadership hire focused on revenue growth indicate potential for upsell into mid-market pharma clients and expansion of late-phase trial services and specialized studies.

Service expansion Comprehensive early phase capabilities (FIH/SAD/MAD, BA/BE, cardiac safety, DDI/FDI, special populations) paired with late-phase clinical trial management suggests cross-selling opportunities into pharma programs seeking integrated turnkey development solutions across multiple therapeutic areas.

Operations readiness Existing clinical pharmacology units in multiple U.S. locations and a seasoned management team emphasize the ability to scale studies, support site access for diverse patient populations, and meet client timelines, which is attractive for sponsors prioritizing reliability and speed to market.